Management
Robert V. Farese Jr, MD
CEO & BOARD MEMBER
-
Bob Farese, Jr, is a physician-scientist whose research at UCSF, Harvard, and Memorial Sloan Kettering has explored the cell biology and lipid metabolism underlying neurodegeneration. He co-founded the Bluefield Project to Cure FTD, and led its discovery science efforts, and recently co-founded Kestrel Neuroscience, a new effort to find and develop therapies for all forms of FTD.
https://www.fwlaboratory.org/
Hubert C. Chen, MD
CONSULTING DIRECTOR
Keri McCormick
EXECUTIVE ADMINISTRATOR
Scientific Advisory Board
Spyros Artavanis-Tsakonas, PhD
Bruce Miller, MD
-
Bruce L. Miller, MD, is an internationally renowned neurologist and expert in neurodegenerative diseases, specializing in the clinical and pathological aspects of dementia. He serves as the Director of the UCSF Memory and Aging Center, where he leads groundbreaking research on frontotemporal dementia, Alzheimer’s disease, and other neurodegenerative conditions. As a member of Kestrel’s Scientific Advisory Board, Dr. Miller brings decades of experience and a deep commitment to advancing innovative approaches for understanding and treating brain disorders.
William Mobley, MD, PhD
Dirk Keene, MD, PhD
-
Dr. Keene is the Nancy and Buster Alvord Endowed Chair and Professor of Neuropathology at the University of Washington. He is the founding director of the UW BioRepository and Integrated Neuropathology (BRaIN) laboratory and Pacific Northwest Brain Donor Network, multiple PI of the Seattle AD Brain Cell Atlas, and leader of multiple neuropathology cores, including the UW ADRC and the CLARiTI consortium. A principal goal for these efforts is to responsibly steward the incredible gift of research brain donation to foster sensible sharing of these biorepository data and tissue resources with researchers to propel effective collaboration and scientific discovery. The primary goals for Dr. Keene’s research lab are to develop, deploy, and promote technologies that accentuate the scientific utility of archived and prospectively acquired human brain tissue, to utilize discoveries derived from these critical resources to develop and test hypotheses in experimental systems, and to apply this knowledge to develop therapeutic strategies.
Roy Parker, PhD
-
Roy Parker is an HHMI Investigator and a Distinguished Professor of Biochemistry at the University of Colorado Boulder. His research addresses the function and regulation of RNA molecules including the role of RNAs and RNA binding proteins in tauopathies and repeat expansion disorders.
Gia Voeltz, PhD
Board of Directors
Roy Richards Jr.
CHAIR
Mike McCune, MD, PhD
BOARD MEMBER
Robert V. Farese Jr, MD
CEO & BOARD MEMBER
-
Bob Farese, Jr, is a physician-scientist whose research at UCSF, Harvard, and Memorial Sloan Kettering has explored the cell biology and lipid metabolism underlying neurodegeneration. He co-founded the Bluefield Project to Cure FTD, and led its discovery science efforts, and recently co-founded Kestrel Neuroscience, a new effort to find and develop therapies for all forms of FTD.
https://www.fwlaboratory.org/
Steve Miller, MD
BOARD MEMBER
Nancy Richards Farese
BOARD MEMBER